Lumexa Imaging Holdings, Inc. income statement LMRI

In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Lumexa Imaging Holdings, Inc. reported revenue of $264.2 million. Net income was $2.7 million, a profit margin of 1.0%. Operating income came to $23.0 million, an operating margin of 8.7%. Diluted earnings per share were $0.03.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Revenue
—
264
253
Selling, general and administrative
—
24
20
Operating income
—
23
19
Other non-operating income (expense)
—
-17
—
Pretax income
—
6
3
Income tax
—
3
1
Net income
—
3
2
Basic EPS
—
0.03
0.02
Diluted EPS
—
0.03
0.02
Weighted average shares, basic
—
96
96
Weighted average shares, diluted
—
96
96
Other measures
Depreciation and amortization
—
10
10
EBITDA
—
33
29
Interest coverage
—
1.42x
1.19x
Margins
Operating margin
—
8.72%
7.69%
Pretax margin
—
2.18%
1.22%
Profit margin
—
1.04%
0.68%
EBITDA margin
—
12.54%
11.62%
Effective tax rate
—
52.39%
44.27%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
LMRI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Raleigh, NC
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2071288

Other Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.